Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)

October 31, 2013 updated by: Boehringer Ingelheim

A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis

To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA)

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

180

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
      • Cerqueira César, Brazil
        • 107.235.61
      • Santa Cecília, Brazil
        • 107.235.62
      • Sao Paulo, Brazil
        • 107.235.60
  • Mexico
      • México, D.F., Mexico
        • 107.235.40
  • Ukraine
      • Kharkov, Ukraine
        • 107.235.71 Institute of Children and Adolescents Health
      • Kiev, Ukraine
        • 107.235.70 Children Clinical Hospital No. 1
      • Kiev, Ukraine
        • 107.235.72 Institute of Pediatrics
      • Kiev, Ukraine
        • 107.235.73 2nd Children Specialized Clinical Hospital "OHMADIT"
  • United States
    • Arkansas
      • Little Rock, Arkansas, United States
        • 107.235.23 Arkansas Children's Hospital
    • California
      • Madera, California, United States
        • 107.235.17 Valley Children's Hospital
      • San Diego, California, United States
        • 107.235.37
    • Colorado
      • Denver, Colorado, United States
        • 107.235.4 Boehringer Ingelheim Investigational Site
    • Connecticut
      • Hartford, Connecticut, United States
        • 107.235.12 Boehringer Ingelheim Investigational Site
    • Delaware
      • Wilmington, Delaware, United States
        • 107.235.13 Alfred I. DuPont Hospital for Children
    • Florida
      • Del Ray Beach, Florida, United States
        • 107.235.36 Arthritis Associates Clinical Research of South Florida
      • Miami, Florida, United States
        • 107.235.21 Miami Children's Hospital
      • St. Petersberg, Florida, United States
        • 107.235.38 Clinical Research Dept #7006
    • Illinois
      • Chicago, Illinois, United States
        • 107.235.8 Boehringer Ingelheim Investigational Site
    • Kansas
      • Kansas City, Kansas, United States
        • 107.235.7 Boehringer Ingelheim Investigational Site
    • Kentucky
      • Louisville, Kentucky, United States
        • 107.235.25 University of Louisville
    • Louisiana
      • New Orleans, Louisiana, United States
        • 107.235.16 Children's Hospital - Department of Rheumatology
    • Massachusetts
      • Boston, Massachusetts, United States
        • 107.235.26 Deparment of Rheumatology
    • Minnesota
      • Rochester, Minnesota, United States
        • 107.235.2 E15 Mayo Clinic
    • Missouri
      • St. Louis, Missouri, United States
        • 107.235.18 Washington University School of Medicine
      • St. Louis, Missouri, United States
        • 107.235.9 Boehringer Ingelheim Investigational Site
    • Nebraska
      • Omaha, Nebraska, United States
        • 107.235.31 Department of Pediatrics
    • New Jersey
      • Livingston, New Jersey, United States
        • 107.235.35 Arthritis and Rheumatic Disease Center
    • New York
      • Buffalo, New York, United States
        • 107.235.24 The Children's Hospital of Buffalo
      • New York, New York, United States
        • 107.235.19 Columbia Presbyterian Medical Center
    • Oklahoma
      • Oklahoma City, Oklahoma, United States
        • 107.235.22 Oklahoma Medical Research Foundation
      • Tulsa, Oklahoma, United States
        • 107.235.33 Healthcare Research Consultants
    • Pennsylvania
      • Duncansville, Pennsylvania, United States
        • 107.235.32 Arthritis and Osteoporosis Center
    • Rhode Island
      • Providence, Rhode Island, United States
        • 107.235.39 Division of Ambulatory Pediatrics
    • Texas
      • Dallas, Texas, United States
        • 107.235.10 Texas Scottish Rite Hospital
    • Utah
      • Salt Lake CIty, Utah, United States
        • 107.235.1 University of Utah School of Medicine
    • Washington
      • Seattle, Washington, United States
        • 107.235.30 Children's Hospital
    • Wisconsin
      • Milwaukee, Wisconsin, United States
        • 107.235.20 Medical College of Wisconsin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

2 years to 17 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • diagnosis of juvenile idiopathic arthritis (JIA) by International League of Associations for Rheumatology (ILAR) criteria; pauciarthritic, extended pauciarthritic, or polyarthritic current course of disease;
  • active arthritis of at least 2 joints
  • at least 2 other abnormal variables of the 5 remaining core set parameters
  • require nonsteroidal anti-inflammatory drugs (NSAIDs)
  • children aged 2-17 years

Exclusion Criteria:

  • systemic course of juvenile idiopathic arthritis
  • all rheumatic conditions not included in inclusion criteria; any clinical finding or abnormal clinically relevant lab (not due to JIA) that could interfere with conduct of clinical trial
  • weight of 9 kg or less
  • pregnancy or breast feeding
  • females of childbearing potential who are sexually active and not using adequate contraception for at least 3 mos prior to and for duration of study
  • history of bleeding disorder, gastrointestinal bleeding, or cerebrovascular bleeding
  • peptic ulcer past 6 months
  • more than 1 disease modifying anti-rheumatic drug (DMARD) or change in DMARD during 3 months prior
  • change corticosteroids during 1 month prior
  • systemic corticosteroids greater than 10 mg/d, hydroxychloroquine greater than 10/mg/d, cyclosporine greater than 5 mg/kg/d., methotrexate greater than 15 mg/m2/wk, cytotoxic agents, gold, D-penicilamine, sulfasalazine, glucosamine, and investigational products
  • etanercept during 1 month prior; infliximab during 2 months prior; intra-articular corticosteroids during 1 month prior
  • patients requiring concomitant other NSAID including topical (excluding ophthalmic)
  • requirement for use of other NSAIDs, anticoagulants, phenothiazine, lithium, or ACTH
  • insufficient effect or intolerability to naproxen or meloxicam
  • known or suspected hypersensitivity to trial meds or their excipients
  • requirement of chronic H2 antagonist
  • history of asthma, nasal polyps, angioneurotic edema, or urticaria with aspirin or NSAIDs
  • planned surgical procedures during study
  • investigational drug exposure during this trial or within 30 days (or 6 half lives, whichever greater) prior
  • previous participation in this trial
  • patients with known drug or alcohol abuse
  • patient, parent or legal representative unable to understand and to comply with protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Interventional Model: Parallel Assignment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Responder rate by core set of outcome criteria (Juvenile Rheumatoid Arthritis Pediatric 30): global assessment disease activity; functional disability, number joints arthritis, limited motion; erythrocyte sedimentation rate;
Time Frame: week 12
week 12

Secondary Outcome Measures

Outcome Measure
Time Frame
Individual core set outcome criteria; final global assessment of efficacy; tolerability; AE incidence and intensity; withdrawals; acetaminophen consumption; safety labs: physical examination; hospitalization for gastrointestinal (GI) SAE, GI AE
Time Frame: weeks 4, 8, 12, 18, and 24
weeks 4, 8, 12, 18, and 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boehringer Ingelheim

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2000

Primary Completion (Actual)

June 1, 2003

Study Registration Dates

First Submitted

May 2, 2002

First Submitted That Met QC Criteria

May 2, 2002

First Posted (Estimate)

May 3, 2002

Study Record Updates

Last Update Posted (Estimate)

November 1, 2013

Last Update Submitted That Met QC Criteria

October 31, 2013

Last Verified

October 1, 2013

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 107.235

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Arthritis, Juvenile Rheumatoid

Clinical Trials on meloxicam oral suspension

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe